Gaucher Disease Type 1

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

GBA, SNCA, CHIT1, ACE, SCARB2, FBXO11, MSH6, GBAP1, CYP2D6, TNF, VDR, UGCG, H4C13, H4C5, H4C14, H4C2, SF3B1, BDNF, ABCG8, TET2, GBA3, HAMP, ABCG5, H4C3, PINK1, H4-16, ASXL1, PLF, H4C8, H4C9

GBA, SNCA, CHIT1, ACE, SCARB2, FBXO11, MSH6, GBAP1, CYP2D6, TNF, VDR, UGCG, H4C13, H4C5, H4C14, H4C2, SF3B1, BDNF, ABCG8, TET2, GBA3, HAMP, ABCG5, H4C3, PINK1, H4-16, ASXL1, PLF, H4C8, H4C9, H4C11, H4C12, CD34, CTNNB1, DVL1, DVL2, GJB2, HFE, TNFRSF11B, PAFAH1B1, PSAP, SLC6A3, YWHAE, BTF3P11, H4C1, H4C4, H4C6, H4C15

Drugs

(1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt, Alglucerase ( CEREDASE ), Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Eliglustat ( CERDELGA ), Imiglucerase ( CEREZYME ), Isofagomine tartrate, Miglustat ( MIGLUSTAT DIPHARMA, MIGLUSTAT GEN. ORPH, YARGESA, ZAVESCA ), Taliglucerase alfa ( ELELYSO ), Velaglucerase alfa ( VPRIV ), Venglustat, adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Gaucher disease type 1 (GD1) is the most common form of Gaucher disease. Like other types of Gaucher disease, GD1 is caused when not enough glucocerebrosidase (GBA) is made. GBA is an important enzyme that breaks down a fatty chemical called glucocerebroside. Because the body cannot break down this chemical, fat-filled Gaucher cells build up in areas like the spleen, liver and bone marrow. Unlike type 2 and 3, GD1 does not usually involve the brain and spinal cord (central nervous system). Symptoms of GD1 include enlarged spleen and liver, low blood cell counts, bleeding problems and bone disease. The symptoms can range from mild to severe and may appear anytime from childhood to adulthood. Gaucher disease is caused by changes (mutations) in the GBA gene and is inherited in an autosomal recessive manner. Diagnosis is suspected by clinical symptoms and confirmed by measuring GBA enzyme activity or genetic testing. Treatments may include enzyme replacement therapy or medications that affect the making of fatty molecules (substrate reduction therapy).